Coya expects to complete ALSTARS Phase 2 ALS trial enrollment in 2H 2026
Company plans to initiate Phase 2 study of COYA 302 in FTD in 2H 2026
Coya says cash is sufficient to fund operations into 2H 2027
Overview
U.S. biotech firm's Q2 collaboration revenue steady yr/yr at $0.2 mln
Q2 net loss widened to $6.6 mln as R&D expenses rose
Result Drivers
R&D EXPENSES - Co said higher Q2 research and development expenses were mainly due to increased preclinical and clinical product candidate costs for COYA 302 ALS Phase 2 trial
LOWER ADMIN COSTS - Co said general and administrative expenses fell due to reduced professional services and employee compensation
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Coya Therapeutics Inc is $16.00, about 244.8% above its August 10 closing price of $4.64
COYA•
